A Scoping Review of Population Diversity in the Common Genomic Aberrations of Clear Cell Renal Cell Carcinoma
Oncology · 2024
DOI: 10.1159/000541370 ↗Kurz gefasst
Scoping Review in der Zeitschrift Oncology, 2024. Verfasst von Sean S Kumar und 5 weiteren Autor:innen. Beteiligte Einrichtung: Macon and Joan Brock Virginia Health Sciences Eastern Virginia Medical School at Old Dominion University, Norfolk, Virginia, USA. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Introduction
Previous literature has shown that clear cell renal cell carcinoma (ccRCC) is becoming a more prevalent diagnosis and that the incidence and mortality differ both regionally and racially. While the molecular profiles for ccRCC are studied regionally through biopsy and sequencing techniques, the genomic landscape and ccRCC diversity data are not well studied. We conducted a review of the known genomic data on 6 of the most clinically relevant DNA biomarkers in ccRCC: von Hippel-Lindau (vHL), Polybromo‐1 (PBRM1), Breast Cancer Gene 1‐Associated Protein 1 (BAP1), Histone-Lysine N‐Methyltransferase Domain‐Containing 2 (SETD2), Mammalian Target of Rapamycin (mTOR), and Lysine‐Specific Demethylase 5C (KDM5C). The review compiled genomic diversity data, incidence, and risk factor differences by geographical and racial cohorts.
Methods
The review methodology was created using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) principles from articles on PubMed and Embase through July 31, 2023, written and published in English, with diagnoses of primary or metastatic ccRCC via cytology or pathology, recorded the incidence of one or more of the 6 biomarkers, explored gene aberration via sequencing, were epidemiological in nature, and/or discussed basic science research, cohort studies, or retrospective studies.
Results
Aberrations in vHL, PBRM1, and SETD2 driving ccRCC are studied frequently, but the data are heterogeneous, whereas there is a paucity in the data regarding KDM5C, PBRM1, and mTOR mutations.
Conclusion
Studying the genetic aberrations that frequently occur in different regions gives insight into what current research lacks. When more genomic landscape research arises, precision therapy, risk calculators, and artificial intelligence may help better prognosticate and individualize treatment for those at risk for ccRCC. Provided the scarcity of existing data, and the rising prevalence of ccRCC, more studies must be conducted at the clinical level.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Macon and Joan Brock Virginia Health Sciences Eastern Virginia Medical School at Old Dominion University, Norfolk, Virginia, USA.
- Children's Hospital Los Angeles, Los Angeles, California, USA.
- Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA.
- Radiomics Lab, University of Southern California, Los Angeles, California, USA.
- Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
- Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Förderung
- NCI NIH HHS
Zitieren
APA
Kumar, S. S., Khandekar, N., Dani, K., Bhatt, S. R., Duddalwar, V., & D'Souza, A. (2024). A Scoping Review of Population Diversity in the Common Genomic Aberrations of Clear Cell Renal Cell Carcinoma. Oncology. https://doi.org/10.1159/000541370
Vancouver
Kumar SS, Khandekar N, Dani K, Bhatt SR, Duddalwar V, D'Souza A. A Scoping Review of Population Diversity in the Common Genomic Aberrations of Clear Cell Renal Cell Carcinoma. Oncology. 2024. doi:10.1159/000541370
BibTeX
@article{Kumar2024,
author = {Kumar, Sean S and Khandekar, Ninad and Dani, Komal and Bhatt, Saina R and Duddalwar, Vinay and D'Souza, Anishka},
title = {A Scoping Review of Population Diversity in the Common Genomic Aberrations of Clear Cell Renal Cell Carcinoma},
journal = {Oncology},
year = {2024},
doi = {10.1159/000541370}
}
EUVIMED